Archaeosomes as drug and vaccine nanodelivery systems

DOIResolve DOI:
AuthorSearch for: ; Search for:
TypeBook Chapter
Book titleNanocarrier Technologies
Pages1740; # of pages: 24
AbstractArchaeosomes, liposomes made from the polar lipids extracted from the membranes of Archaea, have been extensively studied for potential applications in drug and vaccine delivery over the past decade only. Archaeosomes offer significant advantages as nanodelivery vesicles over conventional liposomes made from the ester lipids found in Eukarya and Bacteria. The regularly branched, usually fully saturated isopranoid chains of archaeal polar lipids are attached to the sn-2, 3 carbons of the glycerol backbone(s) via ether bonds. In addition to monopolar lipids, as commonly found in eukaryotic and bacterial polar lipids, membrane-spanning bipolar lipids are encountered in archaeal species. These distinct features of archaeal polar lipids confer relatively superior physico-chemical stability properties to archaeosomes, such as thermal stability, stability in serum, stability at extremes of pH range, resistance to oxidative stress, and against the action of phospholipases and bile salts. Extensive in vitro and in vivo murine model studies indicate that archaeosomes are safe. These properties are beneficial for nanodelivery vesicle applications in biotechnology. Additionally, archaeosomes have been shown to be highly efficacious as self- adjuvanting vaccine delivery vesicles that promote robust, antigen- specific, humoral and cell-mediated immune responses, including CD8 + CTL responses, to encapsulated protein antigens. These immune responses are well sustained over time, and are subject to strong memory responses. In murine models, archaeosome-delivered vaccines have demonstrated strong, long-lasting protective immunity against intracellular pathogens, as well as prophylactic and therapeutic efficacies against the development of experimental cancers. The archaeosome nanodelivery system is now ready for progressing from the laboratory to evaluations for actual commercial applications.
Publication date
AffiliationNational Research Council Canada; NRC Institute for Biological Sciences
Peer reviewedNo
NRC numberPATEL2006
NPARC number9365291
Export citationExport as RIS
Report a correctionReport a correction
Record identifiere14c0e81-1846-4ec1-9820-4c3a76711c65
Record created2009-07-10
Record modified2016-05-09
Bookmark and share
  • Share this page with Facebook (Opens in a new window)
  • Share this page with Twitter (Opens in a new window)
  • Share this page with Google+ (Opens in a new window)
  • Share this page with Delicious (Opens in a new window)